Page 21«..10..20212223..3040..»

The first Virtual Microscope of the human brain, developed by Darmiyan, accurately measures Alzheimer’s-related abnormalities – PRNewswire

§ August 12th, 2020 § Filed under Nano Medicine Comments Off on The first Virtual Microscope of the human brain, developed by Darmiyan, accurately measures Alzheimer’s-related abnormalities – PRNewswire

"Darmiyan's AI, machine learning algorithm using unique MRI microscopic voxel analysis with macroscopic input has generated a very sensitive and specific five year prognosis for patients presenting with amnestic MCI," noted Jamshid Ghajar, MD, PhD, FACS, Moghadam Family Director of Stanford Medicine Brain Performance Center. "This technology has high test-retest reliability and can be applied to any clinical grade MRI which is a very useful clinical tool to assist doctors advising patients with early memory complaints."

"Darmiyan's vision excited me because it offers a biologically-based, objective, and sensitive method for detecting changes in the brain that may first show up as subtle changes in memory and cognition and later, as neurodegenerative disease progresses, lead to more serious cognitive and functional deficits. The promise of a new tool that can give patients and their doctors a head start in planning for and possibly even heading off the advance of dementia is exactly what is needed right now, as the aging population grows larger. With the successful conclusion of this project, Darmiyan moves a step closer to delivering on this promise," said Bradley Buchsbaum, PhD, Cognitive Neuroscience Associate Professor at University of Toronto, Senior Scientist at Baycrest Institute & Rotman Research Institute, and the Principal Investigator of the Canadian arm of Darmiyan's validation project.

Validating BrainSeeon Both Clinical-grade and Research-grade Data

The current study showed that BrainSee performs with as high accuracy on clinical-grade data (from patients who present to clinics and hospitals) as it had previously performed on research-grade data (from patients who volunteer for research or clinical trials). This makes BrainSee the first cutting-edge solution that can be easily integrated in any community clinical setting around the world, not just the high-end academic institutions.

A blind retrospective analysis was previously conducted on 411 amnestic mild cognitive impairment (aMCI) patients with research-grade input data (MRI: 3D T1, T2, DTI; plus MMSE & CDR) reporting 90+% performance accuracy. In the current third-party validation study, external investigators blind-tested BrainSee on 107 new patients with clinical-grade input data (routine clinical T1, T2, DWI; plus MMSE & estimated CDR from clinician notes).

While all 107 patients held the same clinical diagnosis label of aMCI, BrainSee visualized and quantified microstructural differences that existed in each patient's brain, and predicted if they would convert to Alzheimer's dementia within 5 years (converter) or stay stable/ improve (non-converter). Investigators compared BrainSee's predictions against the actual clinical diagnosis five years later. The overall predictive accuracy of BrainSee was reported as 91% (Sensitivity 90%, Specificity 92%)."Such an accurate and non-invasive prognostic tool is non-existent in the market today," noted the US investigators.

The current study also included a separate analysis for evaluating BrainSee's test-retest reliability on 84 additional aMCI patients who were recruited to get two brain MRI scans on the same day: one clinical-grade and one research-grade. The test-retest reliability (consistency) of BrainSee was reported very high, with a correlation coefficient of 99.5%.

With this external validation data, the total number of aMCI patients tested by BrainSee has reached 602.

Novel Technological Advantages

"While reading brain PET scans at Stanford & NYU hospitals as a radiologist, I imagined the day when we could help clinicians visualize and evaluate brain health more comprehensively and objectively while posing less discomfort to patients. That day has come now and Darmiyan's BrainSee technology can finally bring clarity to the field of Alzheimer's through visualizing brain tissue microstructure for doctors. Darmiyan's Virtual Microscope technology unlocks the enormous informative potential of the currently underutilized brain MRI scans," said Darmiyan's Chief Medical and Technology Officer, Kaveh Vejdani, MD. "The huge advantage of MRI modality over PET is that it is safer (no radiation exposure), faster, more cost-efficient, non-invasive (does not require radiotracer injection), and much more widely available throughout the world."

According to Dr. Michael G. Harrington, FRCP, Scientific Director of Neuroscience, HMRI, "Objective measures such as Darmiyan's BrainSee that can predict cognitive decline are strongly needed to recognize and monitor potential therapies."

Meeting Today's Clinical Needs

Alexandra Papaioannou, MD, Executive Director, and George Ioannidis, PhD, Associate Scientific Director of GERAS Centre at HHS (both Professors of Medicine at McMaster University) noted that Darmiyan's non-invasive technology "could result in an important development in the Alzheimer's field" as it has "performed well in predicting disease progression" and can "improve clinicians' workflow and how patients are monitored."

David J. Mikulis, MD, Professor and Director of the JDMI (Joint Department of Medical Imaging) Functional Neuroimaging Research Lab, UHN, noted: "I was impressed by the potential of this breakthrough technology. All study investigators are optimistic that Darmiyan's solution will be successful providing a much needed predictor of disease progression. It may therefore fill a significant diagnostic gap highly valued by patients, clinicians, and clinical researchers."

"With the great help of our clinical trials sites in the US and Canada, we demonstrated that BrainSee can well integrate in the clinical workflow without imposing any limitations, such as specific MRI protocol, in the process of monitoring MCI patients," said Darmiyan's CEO Padideh Kamali-Zare, PhD. "These data support our vision to make BrainSee readily accessible for all people worldwide addressing the dire need for accurate diagnosis of Alzheimer's disease and prognosis of mild cognitive impairment in clinics and clinical trials. Localizing and quantifying early signs of brain cell distortion, in a way that is agnostic to specific protein-based biomarkers such as amyloid or tau, is key to understanding the disease pathology early on in its process and providing personalized treatments suitable for each Alzheimer's patient in the future."

About Darmiyan, Inc.

Darmiyan(based in San Francisco, CA) was incorporated in September 2016 and backed by Y-Combinator (YC) in Summer 2017. The Company has won numerous awards and recognitions including the TEDMED Hive Innovator in 2018 and CABHI Innovation Award in 2019. Darmiyan's most recent funding in 2020 was led by the global pharma giant Eisai with participation of YC and IT-Farm.

SOURCE Darmiyan

Home

Read more from the original source:
The first Virtual Microscope of the human brain, developed by Darmiyan, accurately measures Alzheimer's-related abnormalities - PRNewswire

Read the Rest...

Want healthier, cleaner skin? The answer could be to stop showering – Telegraph.co.uk

§ August 12th, 2020 § Filed under Nano Medicine Comments Off on Want healthier, cleaner skin? The answer could be to stop showering – Telegraph.co.uk

Since the 2016 experiment, hes begun showering again, though far less frequently than before and in a way that would likely seem unusual to the average Brit. I take short, quick showers that arent hot, he explains and uses nothing but water. It gives me a rinse, makes my hair lay down, and makes me feel like theres some divide between night and day in this pandemic time, especially. He also brushes his teeth I dont want them to rot, he points out and uses hand soap. I wash my hands because I dont want to have diseases, he says. Im deliberate about why Im doing what Im doing, and I cut out the things Ive just been doing unquestionably.

Things many of us have been doing unquestionably may mean a step away from teeth whitening kits. Teeth whitening is a great example, he says. Its very much social, and about beauty. But it doesnt actually have to do with hygiene, and it doesnt mean your teeth arent free of bacteria and you dont have an oral infection. But as with the rise and changing face of soap during the Industrial Revolution, so the rise of kits to bleach the stains from our teeth mimics the past, intertwining health and beauty together inexorably.

In the book, Hamblin explains how the use of soap was a social signifier. There was great social value in knowing you werent part of the people living next to the open sewage piles that were in London and elsewhere, he says. You were part of the washed class because you could afford soap and water. The product was expensive, and it demonstrated that you were a cut above the rest. But the Industrial Revolution changed that: now, soap could be made cheaply en masse, and was available to most people to use as a way of maintaining their hygiene and safety.

Soap manufacturers then pivoted. They needed a way to continue to sell that class of beauty, says Hamblin. They produced more expensive soaps, only for luxury purposes. Chemically it was almost an identical product, but with two different consumer entry points and supposed additional value. And so theyve continued today in the same vein: cheaper, bulk-buy soaps lack the colouring and scent that more expensive ones do. Were also bombarded with messages about added ingredients that transform the humble bar of soap into something luxe and with that comes added cost.

Showers for Hamblin have started to serve a different purpose to most people: rather than being to keep clean, they signify the start of his day. This is an odd time, and at times like this, it becomes important to do things that ground you, he explains. Whether its making your bed, eating at rigid meal times or dressing up for working from home, certain rituals are important in keeping us grounded. These markers are important to us to maintain the rhythms of how our minds and bodies are meant to function, he says.

Where he wont compromise on cleanliness is in hand washing. Hands, face, space may be the phrase of the moment, uttered by the prime minister every other breath, but the importance of soap and water isnt lost on the doctor. Its the one instance where he thinks the line between health and beauty is becoming more distinct and its thanks to the coronavirus.

The moment right now with the pandemic is very important, he says. Humans are starting to ask: What is the necessary, important hygienic practice to prevent the spread of disease and what are we doing for all the other reasons? Hamblin believes that the books release comes at a good time because the public are more receptive to rethinking their beliefs. Moments of crisis like this tend to have the effect of resetting peoples value systems, he says. Most people are probably insecure about their health, their financial status, their social systems. Its moments like this where people take stock of what really matters.

Read the original here:
Want healthier, cleaner skin? The answer could be to stop showering - Telegraph.co.uk

Read the Rest...

Novartis : receives EC approval for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps – Marketscreener.com

§ August 12th, 2020 § Filed under Nano Medicine Comments Off on Novartis : receives EC approval for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps – Marketscreener.com

Basel, August 6, 2020 - Novartis today announced that the European Commission (EC) has approved Xolair (omalizumab) as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe chronic rhinosinusitis with nasal polyps (CRSwNP) for whom therapy with INC does not provide adequate disease control1. Phase III studies have shown that Xolair reduces nasal polyp size (defined by Nasal Polyp Score; NPS) and improves symptoms and quality of life in patients with CRSwNP5. Xolair is the first treatment for CRSwNP specifically targeting and blocking immunoglobulin E (IgE), a key driver in the inflammatory pathway of this disease.

'People with chronic rhinosinusitis with nasal polyps can experience significant quality of life impairment as a result of their symptoms. The symptoms include long-term nasal congestion and blockage, sleep disruption and loss of smell and taste,' said Lars Ingemann, Academic Director, EUFOREA*. 'The EUFOREA* patient advisory board welcomes today's approval, which will provide an additional treatment option to patients with severe chronic rhinosinusitis with nasal polyps.'

*EUFOREA: The European Forum for Research and Education in Allergy and Airway Diseases

About Xolair (omalizumab) Xolair is the only approved anti-immunoglobulin E (IgE) antibody treatment specifically designed to target and block IgE. By reducing free IgE, down-regulating high-affinity IgE receptors and limiting mast cell degranulation, Xolair minimizes the release of mediators throughout the allergic inflammatory cascade.

An injectable prescription medicine, Xolair is approved for the treatment of moderate-to-severe or severe persistent allergic asthma in more than 100 countries, including the US since 2003 and the EU since 2005. Xolair is approved for the treatment of chronic spontaneous urticaria in over 90 countries including the EU and for chronic idiopathic urticaria (CIU), as it is known in the US and Canada. Xolair has over 1.3 million patient years of exposure. In addition, a liquid formulation of Xolair in pre-filled syringes has been approved in the EU and in more than 20 countries outside of the EU, including Canada, the US and Australia. The self-administration indication for Xolair in pre-filled syringes was also approved in the EU in 2018, and has since been approved in several other countries, including Australia, Taiwan, Argentina and Brazil. In the US, Novartis and Genentech, Inc. work together to develop and co-promote Xolair. Outside of the US, Novartis markets Xolair and records all sales and related costs.

For chronic rhinosinusitis with nasal polyps (CRSwNP), Xolair is indicated in the EU as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe CRSwNP for whom therapy with INC does not provide adequate disease control1.

About Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Chronic rhinosinusitis with nasal polyps (CRSwNP) impacts up to 4% of people worldwide. It is a potentially debilitating condition in adults that is characterized by inflammation of the nose and paranasal sinuses with the presence of benign inflammatory polyps (nasal polyps) on the lining of the nasal sinuses or nasal cavity, which can block normal airflow2-4. It is possible to have a single polyp or several, and the size of the polyps can vary from microscopic to several centimeters6,7.

Symptoms can include nasal blockage/obstruction, nasal congestion, nasal discharge, facial pain/pressure and reduction in, or loss of, sense of smell2,3. CRSwNP is diagnosed by a physical examination with endoscopy. The condition can be associated with asthma, cystic fibrosis and aspirin sensitivity8. It is also associated with significant morbidity and decreased health-related quality of life, with quality of life impairment9-14. Patients with CRSwNP experience significantly lower health-related quality of life than the general population, with a greater impact for patients with more severe disease, other conditions (comorbidities) or whose CRSwNP has not responded to treatment (refractory disease)12.

Currently, after standard of care intranasal corticosteroids (INC), surgery and systemic corticosteroids are the main treatments for this disease all over the world. Many patients choose them; however, they are often not effective in controlling chronic symptoms over time, due to nasal polyp regrowth. After sinus surgery, nasal polyps recur in up to 80% of people, with approximately 40% requiring at least one additional surgery9. Approximately 80% of people remain uncontrolled 3-5 years after sinus surgery15.

Disclaimer This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'plan,' 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'seek,' 'look forward,' 'believe,' 'committed,' 'investigational,' 'pipeline,' 'launch,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

About Novartis Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews For Novartis multimedia content, please visit https://www.novartis.com/news/media-library For questions about the site or required registration, please contact [email protected]

References 1. Xolair (omalizumab). SmPC 2. Stevens WW, Schleimer RP, Kern RC. Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract 2016;4(4):565-572. 3. Newton JR and Ah-See KW. A review of nasal polyposis. Ther Clin Risk Manag 2008;4(2):507-512. 4. Bachert C. Evidence-based management of nasal polyposis by intranasal corticosteroids: from the cause to the clinic. Int Arch Allergy Immunol 2011;155(4):309-321. 5. Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: two randomized phase III trials. J Allergy and Clin Immunol 2020. doi.org/10.1016/j.jaci.2020.05.032 [online ahead of print]. 6. Patient. Nasal Polyps [online] February 24, 2017. Available from: https://patient.info/ears-nose-throat-mouth/nasal-polyps-leaflet [Last accessed: August 2020]. 7. Johns Hopkins Medicine. Could nasal polyps be the cause of your stuffy nose? Available from: https://www.hopkinsmedicine.org/health/articles-and-answers/ask-the-expert/stuffy-nose-nasal-polyps [Last accessed: August 2020]. 8. World Allergy Organization. Nasal Polyposis: A Multifactorial disease. Available from: https://www.worldallergy.org/educational_programs/world_allergy_forum/sydney/pawankar.php [Last accessed: August 2020]. 9. Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis. J Allergy Clin Immunol 2015;136(6):1431-1440. 10. Erskine S, Hopkins C, Kumar N, et al. A cross sectional analysis of a case-control study about quality of life in CRS in the UK; a comparison between CRS subtypes. Rhinology 2016;54(4):311-315. 11. Hoehle LP, Phillips KM, Bergmark RW, et al. Symptoms of chronic rhinosinusitis differentially impact general health-related quality of life. Rhinology 2016;54(4):316-322. 12. Khan A, Huynh TMT, Vandeplas G, et al. The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life. Rhinology 2019;57(5):343-351. 13. Naclerio R, Baroody F, Bachert C, et al. Clinical research needs for the management of chronic rhinosinusitis with nasal polyps in the new era of biologics. A National Institute of Allergy and Infectious Diseases workshop. J Allergy Clin Immunol Pract 2020;8(5):1532-1549.e1. 14. Ye Z, Sun L, Wang Q. A head-to-head comparison of EQ-5D-5 L and SF-6D in Chinese patients with low back pain. Health Qual Life Outcomes 2019;17(1):57. 15. van der Veen J, Seys SF, Timmermans M, et al. Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre. Allergy 2017;72(2):282-290.

# # #

Novartis Media Relations E-mail: [email protected]

Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: [email protected]

Continue reading here:
Novartis : receives EC approval for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps - Marketscreener.com

Read the Rest...

Healthcare Nanotechnology (Nanomedicine) Market 2020 Size by Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies and…

§ August 12th, 2020 § Filed under Nano Medicine Comments Off on Healthcare Nanotechnology (Nanomedicine) Market 2020 Size by Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies and…

New Jersey, United States,- The most recent Healthcare Nanotechnology (Nanomedicine) Market Research study includes some significant activities of the current market size for the worldwide Healthcare Nanotechnology (Nanomedicine) market. It presents a point by point analysis dependent on the exhaustive research of the market elements like market size, development situation, potential opportunities, and operation landscape and trend analysis. This report centers around the Healthcare Nanotechnology (Nanomedicine) business status, presents volume and worth, key market, product type, consumers, regions, and key players.

The COVID-19 pandemic has disrupted lives and is challenging the business landscape globally. Pre and Post COVID-19 market outlook is covered in this report. This is the most recent report, covering the current economic situation after the COVID-19 outbreak.

Key highlights from COVID-19 impact analysis:

Unveiling a brief about the Healthcare Nanotechnology (Nanomedicine) market competitive scope:

The report includes pivotal details about the manufactured products, and in-depth company profile, remuneration, and other production patterns.

The research study encompasses information pertaining to the market share that every company holds, in tandem with the price pattern graph and the gross margins.

Healthcare Nanotechnology (Nanomedicine) Market, By Type

Healthcare Nanotechnology (Nanomedicine) Market, By Application

Other important inclusions in the Healthcare Nanotechnology (Nanomedicine) market report:

A brief overview of the regional landscape:

Reasons To Buy:

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Packaging Robot Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Packtech Textiles Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Paclitaxel-eluting Stent Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Paint Pigments Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Paintball Gun Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Originally posted here:
Healthcare Nanotechnology (Nanomedicine) Market 2020 Size by Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies and...

Read the Rest...

Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region – Good Night, Good Hockey

§ August 12th, 2020 § Filed under Nano Medicine Comments Off on Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region – Good Night, Good Hockey

Nanomedicine Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/39223

Nanomedicine is an application of nanotechnology, which are used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine usages nanoscale manipulation of materials to improve medicine delivery. Therefore, nanomedicine has facilitated the treatment against various diseases. The nanomedicine market includes products that are nanoformulations of the existing drugs and new drugs or are nanobiomaterials. The research and development of new devices as well as the diagnostics will become, more effective, enabling faster response and the ability to treat new diseases are likely to boost the market growth.

The nanomedicine markets are driven by factors such as developing new technologies for drug delivery, increase acceptance of nanomedicine across varied applications, rise in government support and funding, the growing need for therapies that have fewer side effects and cost-effective. However, long approval process and risks associated with nanomedicine (environmental impacts) are hampering the market growth at the global level. An increase in the out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are likely to create lucrative opportunities in the nanomedicine market.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Nanomedicine Market Segmentation Analysis: Based on the application, the nanomedicine market has been segmented into cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. The oncology segment held the dominant market share in 2018 and is projected to maintain its leading position throughout the forecast period owing to the rising availability of patient information and technological advancements. However, the cardiovascular and neurology segment is projected to grow at the highest CAGR of XX% during the forecast period due to presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.

Nanomedicine Market Regional Analysis: Geographically, the Nanomedicine market has been segmented into North America, the Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Nanomedicine market in 2018 due to the rising presence of patented nanomedicine products, the availability of advanced healthcare infrastructure and the rapid acceptance of nanomedicine. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period thanks to rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are predicted to accelerate the growth of this region in the near future.

Nanomedicine Market Competitive landscape Major Key players operating in this market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc, and Johnson & Johnson. Manufacturers in the nanomedicine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present a comprehensive analysis of Nanomedicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Nanomedicine Market dynamics, structure by analyzing the market segments and project the Nanomedicine Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Nanomedicine Market make the report investors guide. Scope of the Nanomedicine Market:

Nanomedicine Market by Modality:

Diagnostics Treatments Nanomedicine Market by Diseases:

Oncological Diseases Infectious Diseases Cardiovascular Diseases Orthopedic Disorders Neurological Diseases Urological Diseases Ophthalmological Diseases Immunological Diseases Nanomedicine Market by Application:

Neurology Cardiovascular Anti-Inflammatory Anti-Infectives Oncology Nanomedicine Market by Region:

Asia Pacific North America Europe Latin America Middle East Africa Nanomedicine Market Major Players:

Abbott Laboratories CombiMatrix Corporation General Electric Company Sigma-Tau Pharmaceuticals, Inc Johnson & Johnson Mallinckrodt plc. Merck & Company, Inc. Nanosphere, Inc. Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Celgene Corporation UCB (Union Chimique Belge) S.A. AMAG Pharmaceuticals Nanospectra Biosciences, Inc. Arrowhead Pharmaceuticals, Inc. Leadiant Biosciences, Inc. Epeius Biotechnologies Corporation Cytimmune Sciences, Inc.

Browse Full Report with Facts and Figures Report at:https://www.maximizemarketresearch.com/market-report/nanomedicine-market/39223/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Read more:
Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region - Good Night, Good Hockey

Read the Rest...

2020 Market Study on the Future of Therapy: Technology Advances in Drug-device Combination Products – ResearchAndMarkets.com – Press Release – Digital…

§ August 10th, 2020 § Filed under Nanotechnology Journal Comments Off on 2020 Market Study on the Future of Therapy: Technology Advances in Drug-device Combination Products – ResearchAndMarkets.com – Press Release – Digital…

DUBLIN--(Business Wire)--The "Future of Therapy: Technology Advances in Drug-device Combination Products" report has been added to ResearchAndMarkets.com's offering.

Drug device combination products are aimed to provide targeted treatment, enable better drug delivery and improve the efficacy of the device and medicine.

This research service (RS) showcases some of these emerging drug-device combination products including drug eluting stents and drug loaded/coated orthopedic implants under implantable drug-device combination and drug-eluting lens and drug-eluting bandages under non-implantable drug device combinations. The research service discusses the impact of these innovations, patents, technology roadmap and growth opportunities.

Key Topics Covered:

1.0 Executive Summary

2.0 Industry Overview

2.1 Drug-device Combination Products Improving Delivery of Drugs or Therapeutics Efficacy of the Device

2.2 Segmentation of Drug-device Combination Based on Product Type

2.3 Segmentation of Drug-device Combination Based on Application Type

2.4 Growth Opportunity: Drug-device Combinations Improving Performance of Medical Devices

2.5 Growth Opportunity: Drug-device Combination Improves Patients' Acceptance of Medication

3.0 Drug-device Combination Product: Innovation Tracker

3.1 Innovations in Drug-eluting Stents

3.1.1 Drug-eluting Stent to Address the Challenge of in-stent Restenosis

3.1.2 Sirolimus-eluting Coronary Stent with Ultrathin Strut

3.1.3 Zotarolimus-eluting Coronary Stent System

3.1.4 Paclitaxel-eluting Vascular Stent System

3.1.5 Key Companies in Drug-eluting Stent Innovations

3.1.6 The US Leads Patent Activity for Drug-eluting Stents

3.1.7 Key Recent Patents in Drug-eluting Stents to Check

3.2 Innovations in Drug-eluting Contact Lens

3.2.1 Drug-eluting Lens Presenting Growth Opportunities to Replace Ocular Drug Delivery Systems

3.2.2 Drug-eluting Clear Corneal Bandage Lens

3.2.3 Antihistamine-releasing Contact Lens for Ocular Allergy

3.2.4 Digital Printed Drug Layers on Contact Lens for Glaucoma Therapy

3.2.5 Digital-eluting Lens for Treating Corneal Pathologies

3.2.6 Moderate to Low Patent Activity of Drug-eluting Contact Lens with Johnson & Johnson Vision Care Inc., Showing High Activity

3.2.7 Key Recent Drug-eluting Contact Lens Patents to Check

3.3 Innovations in Drug-eluting Bandages

3.3.1 Drug-eluting Wound Care Devices Provide Faster Healing and Eliminate Infections

3.3.2 Chitosan-based Wound Dressing for Hemostatic Effect

3.3.3 Kaolin-based Hemostatic Dressing for Emergency Medical Service

3.3.4 Antimicrobial Impregnated Wound Care Dressings to Avoid Wound Infections

3.3.5 Silver, Iodine, Copper Ions for Antimicrobial Activity in Wound Care Bandages

3.3.6 IP Activity of Drug Releasing Wound Care Bandages/Dressings

3.3.7 Key Recent Drug-eluting Kens Patents to Check

3.4 Drug-eluting Orthopedic Implant

3.4.1 Drug-eluting Orthopedic Implants Offering Better Osteointegration and Protection from Infection

3.4.2 Calcium Scaffold Carrying Antibiotic for Infection Management

3.4.3 Peptide-based Bone Graft for Faster Repair

3.4.4 Doxycycline-eluting Synthetic Bone Substitute

3.4.5 Key Research on Drug-coated Orthopedic Implants

3.4.6 Patent Activity of Drug-loaded Orthopedic Devices Dominated by the US Patents

3.4.7 Key Recent Drug Loaded Bone Scaffold Patents to Check

4.0 Emerging Technology Roadmap and Growth Opportunity

4.1 Emerging Technology Roadmap of Drug-eluting Stents (DES)

4.2 Future of Coronary Stents: Gene Eluting Stents to Overcome Restenosis and Late-stent Thrombosis Challenges

4.3 Drug-eluting Lens Envisions Sensor Technology Convergence into its Product

4.4 Smart Wound Dressing Including Sensor Technology Innovations

4.5 Nanotechnology to Improve the Regenerative Properties of Drug-eluting Bone Scaffold

4.6 Business Growth Opportunities - Patient Centric, Patient Specific, and Cost-effective Imaging Redefining Future of Therapy

4.7 Strategic Imperatives for the Future of the Drug-device Combination Products

5.0 Key Industry Contacts

For more information about this report visit https://www.researchandmarkets.com/r/o6msb5

View source version on businesswire.com: https://www.businesswire.com/news/home/20200810005426/en/

ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Read the original post:

2020 Market Study on the Future of Therapy: Technology Advances in Drug-device Combination Products - ResearchAndMarkets.com - Press Release - Digital...

Read the Rest...

Heat-related Injuries and How to Stay Cool – Newswise

§ August 10th, 2020 § Filed under Nanotechnology Journal Comments Off on Heat-related Injuries and How to Stay Cool – Newswise

Newswise Hot weather is here. That means it's the perfect time to go for a swim or relax in the shade. But before lathering on the sunscreen and heading outdoors, it's important to know the signs of heat-related injuries and how to stay cool when the temperatures soar.

Heat exhaustionincludes heavy sweating, breathlessness, a fast but weak pulse, headache, dizziness and nausea or vomiting. "Heat exhaustion can happen to anyone overexerting themselves in extreme heat," says BIDMC emergency medicine physicianLaura Burke, MD. "If symptoms are severe, call for medical help right away."

Individuals at an increased risk for heat exhaustion include:

Heat exhaustion can escalate to a life-threatening condition calledheat stroke. "During heat stroke, the body can no longer cool itself down through sweating, which can result in damage to major organs," Burke says.

Symptoms include hot and dry skin, a fever higher than 102F, headache, confusion and unconsciousness. "If you see someone suffering from heat stroke, try to cool the person down by getting to shade or into the air conditioning. Apply cool water with wet cloths and call for medical help immediately," Burke says.

Check out these important tips to help you stay cool and healthy in the heat.

Drink plenty of water.Avoid alcohol, which can impact your ability to sweat properly, and caffeine, which is a natural diuretic. "Two glasses of water per hour is the general rule in extreme heat," Burke says.

Dress in light-colored, loose-fitted clothing.Breathable clothing allows sweat to evaporate. In the hot sun, cover up with a hat andsunscreen.

Limit outdoor activity.If you plan to exercise outdoors, avoid peak hours when temperatures are highest. "Try to rest often in shady areas so that your body's thermostat will have a chance to recover," Burke says.

Take a cool shower.Another way to cool down quickly is to take a cool shower or bath, or to place a cool washcloth on your forehead.

Read moresummer health tipsfrom BIDMC experts.

Read this article:

Heat-related Injuries and How to Stay Cool - Newswise

Read the Rest...

Nanotechnology and the Fight Against COVID-19 – AZoNano

§ August 10th, 2020 § Filed under Nanotechnology Journal Comments Off on Nanotechnology and the Fight Against COVID-19 – AZoNano

Image Credit:Lightspring/Shutterstock.com

As the quest for a COVID-19 vaccine continues, researchers working in other areas of science such as nanotechnology have joined the battle against thevirus.

In addition to being responsible for hundreds of thousands of deaths, the COVID-19 crisis has mobilized the scientific community in a way that no other situation has before. Multiple disciplines are currently researching the virus, whether this be developing diagnosis and treatment methods, or a modality to slow its spread.

Nanotechnology is being prepared for deployment in the fight against COVID-19 in a wide range of areas. A new paper published in the journal ACS Nano looks at the different ways in which nanotechnology will be used, with the authors describing the use of nanotech in fields as diverse as virology, biology, medicine, engineering, chemistry, materials science, and computational science.

The nanotechnology breakthroughs made in the coming months and years should not just bolster the resistance against COVID-19, but also help in the fight against other viruses, bacteria, and pathogens.

The authors of the study identified four key stages at which nanotechnology could be introduced to help the battle against COVID-19:

What follows is a rundown of the methods being developed that could be employed in future pandemics and epidemics, possibly preventing them from reaching global crisis status.

The ongoing COVID-19 crisis does not mark the first time that nanomaterials have been highlighted for their ability to limit the spread of viruses. Surfaces coated with polymers containing nanoparticles of metals such as copper can release metal ions, which are known for their antiviral activity and have already been suggested for use in certain areas. The widespread nature of the COVID-19 crisis calls for a corresponding widespread application of such measures.

Click here to find out more about nanoparticle size analyzers

Nanotechnology offers a safer alternative to the use of toxic chemicals such as disinfectants in medical settings. Such coatings are far more convenient than other non-toxic disinfectant measures such as irradiation with ultraviolet (UV) light. These nanomaterial coatings and alloys confer antiviral and antibacterial properties through the release of ions, which disrupt the operation of living cells.

One of the key difficulties in tackling COVID-19 is its hardiness and ability to survive on a variety of surfaces for prolonged periods often days on end. The beauty of a nanomaterial coating is that it could provide protection continuously after just one treatment. This is especially true if the material can be structured in such a way that the release of ions is gradual. Self-disinfecting surfaces would be of great use even after the COVID-19 crisis is over.

Silver, copper and zinc all show intrinsic antimicrobial properties and are already used in medical equipment and healthcare settings.

In unison with our growing understanding of bacteria and viruses, silver nanoparticles have found their way into commercial products such as silver zeolites in paints, and in food trays as a biocide, with the antiviral efficiency of silver nanoparticles demonstrated against a variety of viruses, including HIV-1.

Copper was shown to be effective against polio in the late 1970s and, more recently, was of great use in combating another coronavirus, HuCoV-229E. The virus, which typically lives for around six days on a surface, became inactive in approximately 60 minutes on surfaces coated with copper alloys. The similarity between HuCoV-229E and SARS-CoV-2 points to copper nanoparticles and alloy coatings being a key-player in slowing, if not stopping, the spread.

The authors suggest that copper alloys could also find themselves replacing more traditional stainless steel surfaces and appliances in medical settings as a result of this non-toxic antibacterial agency.

Nanomaterials are also employed in the production of vitally import personal protective equipment (PPE) to help reduce the spread of COVID-19 to frontline medical workers. In particular, nanomaterials could be used in facemasks and other PPE to capture and immobilize viral cells. This task would likely fall upon silver nanoparticles, which have been shown effective in this respect, severely limiting viral activity when loaded into filters.

Find out more about nanomaterials in several industries

However, even if the spread of COVID-19 can be slowed by such coatings and a switch to copper alloys, another vital step in combating COVID-19 is efficient testing and diagnosis. Fortunately, nanomaterials are on hand to aid in this regard too.

The SARS-CoV-2 virus cannot be eliminated from all surfaces, and not all surfaces can be coated with a nanomaterial layer. This means that even with such measures, the transmission is very likely to continue. Therefore, the next step in slowing the spread is the quick and effective diagnosis of those already infected.

The current testing methodology for COVID-19 involves the use of a swab applied to the throat and nasal passage of a potential patient. This swab is then analyzed using a reverse transcription-polymerase chain reaction (RT-PCR) testa procedure used in virology to test for the presence of specific RNA. The use of nanoparticles, however, could provide a more immediate on-site test result without the need to send samples away for lab analysis or the need for expensive equipment.

The principle behind the application is the binding of gold nanoparticles with antibodies and is in its very early planning stages. In the presence of further antibodies collected from the patient, the nanoparticles cluster, shifting the color of the test swab from blue to red. This provides an immediate indication of infection. A test of this nature could be of particular use in developing countries and regions of the world with little to no medical infrastructure.

Image Credit: BERMIX STUDIO/Shutterstock.com

Another alternative to the currently favored RT-PCR test is graphene-based field-effect transistors (FET), which are biosensing devices coupled to a specific antibody against SARS-CoV-2 spike protein. Again, this would be another method of on-site detection of COVID-19 that is cost-effective and delivers a rapid result.

Gold nanoparticles can also be used in nano biosensors, which combine the excellent electrical and optical properties of nanomaterials with biological or synthetic molecules used as receptors to detect specific whole viral cells selectively. This cell-sensing device is based on the reaction of cell surface proteins with specific antibodies conjugated to gold nanoparticles taking advantage of the known antigens and available antibodies.

It should be noted that this is a field in its relative infancy, but any developments spearheaded in response to the COVID-19 crisis could be carried forward to future epidemics and pandemics.

The rapid spread of COVID-19 and the relative failure to tackle it has exposed a weakness in medicine: the lack of a broad-spectrum antiviral drug. That means that when a new virus emerges, there is little in the way of medical intervention that can be done to mitigate the spread. Therefore, drugs that could tackle both COVID-19 and future viruses are of the utmost importance.

Though other organs can be affected, the main target of COVID-19 once inside the body of a sufferer is the respiratory system. In particular, the virus targets the upper respiratory tract and the lungs, with the latter being the most critically affected area. Therefore, the review paper focuses on methods that seek to inactivate the virus in the deep-lung.

Airborne nanomaterials can penetrate the deep-lung, delivering medicine directly to the cells that SARS-CoV-2 uses to spread further into a patients system. Nanomedicine is currently being heavily researched in terms of providing drugs and using beneficial proteins via aerosol nano-devices.

A general antiviral nanomaterial intervention could work by preventing viruses from interacting with and binding to cell membranes. Previous work has shown that this could possibly be achieved by a wealth of nanomaterials such as polymers, liposomes, and small molecules.

However, the implementation of these methods via aerosol has been hampered by the necessary dilution of these nanomaterials, which negatively impacts their effectiveness. This loss of efficiency allows virus cells to begin replication again.

This setback can be combated by nanoparticles that, after introduction to a patients lungs or other organs, attack the virion the infective form of a virus outside a host cellpermanently damaging it and stopping replication.

A specific COVID-19 drug administered in a similar way to the general antiviral treatment discussed above could be created by engineering it to block the S spike protein from interacting with the ACE2 receptor.

Part of the key to saving the lives of COVID-19 patients may not just hinge on attacking the virus, but limiting the bodys response to it.

As a result of the COVID-19 crisis, many more people are familiar with the phrase Cytokine Storm. Cytokine storms are associated with a wide variety of infectious and noninfectious diseases, in particular the H1N1 influenza strain. The term itself summons images of a terrible and violent reaction within the patients body, arising from their excessive immune response.

Although a well-regulated cytokine response that is rapidly triggered by the hosts innate immunity can serve to prevent and counteract infection, an excessive, unbalanced and prolonged immune response can seriously harm the body.

In many COVID-19 cases, this inflammatory storm is responsible for acute respiratory distress syndrome (ARDS), which is often associated with multiple organ failure and a leading cause of death in critical patients.

Nanomaterials have been used to adjust the immune response, bringing it to an optimal level, and could be used to limit the cytokine storm. This can be done in a number of ways.

Firstly, nanotechnology can deliver immunosuppressants to target immune cells and organs, leading to reductions in drug dose, drug distribution to non-target tissues and organs, and, in-turn, unwanted side effects.

Secondly, nanotools can be explicitly designed to evade the immune system and finely tune the patients system to receive a high drug load that could otherwise trigger a harmful immune response.

With regards to COVID-19 specifically, the authors of the review point to the use of nanodiamonds to reduce macrophage infiltrationa process linked to inflammation.

How Could Polymer Nanoparticles Slow the Spread of COVID-19?

COVID-19 has presented the scientific community with the kind of challenge it has perhaps never had to face before, but it has also created the awareness that this situation could arise again.

The nanotech advancements described, while being engineered in response to this current crisis, are designed by scientists with an eye to the future and the next potential pandemic.

The authors of the review paper have a message to the general public, policy-makers, politicians, and the scientific community: we must stop thinking of human health as an isolated phenomenon. Instead, we have to embrace the concept of one health with understanding that our well-being is intrinsically and irreversibly linked with the ecosystems we inhabit.

The field of nanotechnology points towards the benefits of adopting a holistic and inclusive attitude, spreading across so many aspects of science and bringing together scientists from diverse backgrounds, all converging on a multifaceted solution to a crisis that threatens our very way of life.

The study of nanotechnology could emerge such big ideas with the capability of changing the world.

Using Nanotechnology to Identify those Most at Risk from COVID-19

Weiss, C., Carriere, M., Fusco, L., et al. (2020) Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic. ACS Nano.https://doi.org/10.1021/acsnano.0c03697.

Lea, R. (2020) The Development of a New Anti-COVID-19 Nanocoating. [Online] AZO Nano. Available at: https://www.azonano.com/news.aspx?newsID=37294.

Lea. R. (2020) Graphene-Based Masks Launched to Combat COVID-19. [Online] AZO Nano. Available at: https://www.azonano.com/news.aspx?newsID=37431.

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Excerpt from:

Nanotechnology and the Fight Against COVID-19 - AZoNano

Read the Rest...

Nanotechnology in Packaging: An Industry Overview 2010-2030 – Yahoo Finance UK

§ August 10th, 2020 § Filed under Nanotech Comments Off on Nanotechnology in Packaging: An Industry Overview 2010-2030 – Yahoo Finance UK

Dublin, Aug. 07, 2020 (GLOBE NEWSWIRE) -- The "The Global Market for Nanotechnology in Packaging" report has been added to ResearchAndMarkets.com's offering.

Report contents include:

Nanomaterials have already been commercialized at various stages of the packaging supply chain from food storage to traceability and tracking. Their enhanced properties, such as UV protection, barrier to moisture, gases and volatile components, mechanical strength, significantly improve packaging materials.

Nanomaterials-based packaging is used to:

The use of nanomaterials in packaging will play a significant role in:

Nanomaterials utilized in packaging include:

Key Topics Covered

1 INTRODUCTION 1.1 Aims and objectives of the study 1.1.1 Properties of nanomaterials 1.1.2 Categorization

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY 3.1 Active packaging 3.2 Intelligent/smart packaging 3.3 Biobased packaging 3.4 Market drivers and trends 3.4.1 Growing demand for active and smart packaging 3.4.2 Growing demand for renewable plastic packaging 3.4.3 Consumer safety concerns driving demand for antimicrobial surfaces 3.4.4 Sustainability and biodegradability 3.4.5 Replacing petroleum-based, glass, metal, wax/plastic coated products 3.4.6 Improving food quality and safety during transportation 3.4.7 Improved barrier function to increase shelf life 3.4.8 Prevention of food waste 3.4.9 Product safety and anti-counterfeiting 3.5 Market challenges 3.6 Global market revenues for nanopackaging

4 TYPES OF PACKAGING 4.1 Barrier films and coatings 4.2 Antibacterial (antimicrobial) packaging 4.3 Anti-counterfeit packaging 4.4 Temperature controlled packaging 4.5 Food sensors

5 NANOMATERIALS USED IN PACKAGING 5.1 Composites 5.2 Films 5.3 Coatings 5.4 CELLULLOSE NANOFIBERS 5.4.1 Paper and board packaging 5.4.2 Gas barrier sheets 5.4.3 Packaging adhesives 5.4.4 Food packaging coatings 5.4.5 Antibacterial 5.5 CELLULOSE NANOCRYSTALS 5.5.1 Flexible packaging 5.5.2 Plastics for bioplastic packaging 5.5.3 Antimicrobial properties 5.6 GRAPHENE 5.6.1 Properties 5.6.2 Barrier films for food packaging 5.6.3 Anti-bacterial activity 5.6.4 Anti-viral activity 5.7 NANOSILVER 5.7.1 Properties 5.7.2 Antimicrobial and antiviral activity 5.7.3 Nanosilver in packaging 5.8 NANOSILICA 5.8.1 Properties 5.8.2 Nanosilica coated barrier films 5.9 ZINC OXIDE NANOPARTICLES 5.9.1 Properties 5.9.2 Antimicrobial packaging films 5.9.3 Antimicrobial activity 5.10 CARBON NANOTUBES 5.10.1 Properties 5.10.2 Antimicrobial activity 5.10.3 Packaging films 5.11 CHITOSAN NANOPARTICLES 5.11.1 Properties 5.11.2 Packaging coatings and films 5.12 NANOCLAYS 5.12.1 Properties 5.12.2 Barrier films 5.13 TITANIUM DIOXIDE NANOPARTICLES 5.13.1 Properties 5.13.2 Antibacterial films

6 NANOMATERIALS IN THE PACKAGING MARKET 6.1 Applications 6.1.1 Protective coatings and films 6.1.2 Bioplastics packaging 6.1.3 Anti-counterfeiting 6.1.3.1 Nano barcodes and optics 6.1.4 Pharmaceutical packaging 6.2 Global market size

7 COMPANY PROFILES

For more information about this report visit https://www.researchandmarkets.com/r/awmrkg

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Continued here:

Nanotechnology in Packaging: An Industry Overview 2010-2030 - Yahoo Finance UK

Read the Rest...

$2 million awarded to nanotech pioneer Nelumbo Inc. for efficient refrigeration solution, supporting a robust food supply chain – Stockhouse

§ August 10th, 2020 § Filed under Nanotech Comments Off on $2 million awarded to nanotech pioneer Nelumbo Inc. for efficient refrigeration solution, supporting a robust food supply chain – Stockhouse

HAYWARD, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Nelumbo, a pioneer in the field of advanced materials and surface modifications, announced that it has been awarded $2 million in funding from the California Energy Commission (CEC) through their Electric Program Investment Charge (EPIC). The EPIC program invests in scientific and technological research to accelerate the transformation of the electricity sector to meet the state’s energy and climate goals.

The California Energy Commission is proud to provide EPIC funding to support entrepreneurs like Nelumbo that are working to reduce energy use and provide benefits to ratepayers,” said CEC Vice Chair Janea Scott. Nelumbo has created an advanced anti-icing material to improve the energy efficiency of industrial refrigeration systems. Cutting edge technologies like Nelumbo’s have the potential to create energy savings while advancing California’s clean energy goals.”

The purpose of this solicitation is to fund applied research and development projects that enable cost-effective decarbonization of California’s food and beverage processing industry. Nelumbo has proposed to achieve this by advancing its anti-ice materials for deployment on industrial scale refrigeration systems.

Supporting a reliable food supply through advanced anti-icing technology

Industrial refrigeration systems rely on refrigerants for air heat exchangers to create temperature-controlled space. In doing so, the evaporation of the refrigerant removes heat from the air resulting in condensate and frost formation on the heat exchanger coils. Ice and frost formation foul the coil and diminishes the ability of the coil to cool the air, necessitating the ice to be melted off by an energy-intensive defrost process which accounts for over 20% of energy consumption of these refrigeration systems. These defrost cycles must occur though, or else temperatures will rise, and food quality will suffer.

"Recent events have highlighted exactly how critical the robustness of our food supply chain is,” said Nelumbo CEO Liam Berryman. We are pleased to work with the CEC to demonstrate a solution that can be impactful at any scale and to any system. We see this project as an expansion step into a range of new sustainable opportunities in cooling."

Nelumbo has already demonstrated its anti-ice materials on residential refrigerators as well as residential and commercial-scale heat pumps. With this funding, Nelumbo will optimize their materials for industrial substrates and scale manufacturing processes required for commercial adoption.

The CEC has always been a leader in sustainability and energy innovation, and we couldn’t be more excited to have their support on this project,” said Cody Oliver, Director of Manufacturing at Nelumbo and Project Lead for this CEC solicitation. Industrial refrigeration is a prime application for our materials and the massive, complex components provide an opportunity for us to showcase the versatility and scalability of our manufacturing processes. With the provided funding we will be able to accelerate development and seize an opportunity to have a tremendous impact on the State’s energy consumption, grid reliability, and greenhouse gas emissions while also improving food quality and reducing waste.”

About Nelumbo

At Nelumbo, we are committed to providing society with material solutions to resource scarcity and climate change. We see advanced materials as vastly underutilized, with opportunities to revolutionize the built environment and every manufactured good. To facilitate this change, we have created cost-effective, scalable, and sustainable processes to drive the broad adoption of advanced materials in everyday products.

Nelumbo

See the original post:

$2 million awarded to nanotech pioneer Nelumbo Inc. for efficient refrigeration solution, supporting a robust food supply chain - Stockhouse

Read the Rest...

Global Ion Sources Market 2020 to Witness Huge Growth by 2026 | Top Key Players; Hitachi High-Technologies, Evans Analytical Group, Fibics…

§ August 10th, 2020 § Filed under Nanotech Comments Off on Global Ion Sources Market 2020 to Witness Huge Growth by 2026 | Top Key Players; Hitachi High-Technologies, Evans Analytical Group, Fibics…

According to a new report published by Innovate Insights, titled, Global Ion Sources COVID 19 Impact Analysis, In Depth Insight, Growth & Research Finding to 2026 The report has offered an all-inclusive analysis of the global Ion Sources Market taking into consideration all the crucial aspects like growth factors, constraints, market developments, top investment pockets, future prospects, and trends. At the start, the report lays emphasis on the key trends and opportunities that may emerge in the near future and positively impact the overall industry growth.

Note: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Get Free Exclusive Sample of this Premium Report at: https://www.innovateinsights.com/report/global-ion-sources-market-status-by-manufacturers-types/98305/#requestsample

The Ion Sources report provides the comprehensive study of the market. Report gives the in depth analysis on various factors, for example market size, segmentations, competitive landscapes, geographical regions or countries and end users. In addition, research report covers all the qualitative and quantitative features about the Ion Sources markets across the globe. A comprehensive study of the Ion Sources market is described to recognize the several applications of the features of products and usage. The Ion Sources is estimated to see good growth over the forecast period. This report also focuses on all the crucial parameters essential to analyse the keyword market. Report gives the forecasts for sales in terms of volume and value. In addition reports helps participants as it offers value chain optimization, study on marketplace expanding, product launches and technological innovations coming in the market.

Our best analysts have surveyed the market report with the reference of inventories and data given by the key players: Hitachi High-Technologies Evans Analytical Group Fibics Incorporated FEI Carl Zeiss AG ZEROK Nanotech Thermo Fisher Scientific Inc. Intlvac D-Pace NanoLab Tescan Waters

This report particularly focuses on major drivers, opportunities. However, there can be some challenges, risks, restraints, and threats for major vendors over the forecast period. In addition, this report covers extensive analysis on geographical regions. Report covers the leading players which are currently functioning in global Ion Sources industry worldwide. Additionally, revenue forecasts for the major market are provided within the report. This report presents a complete overview about the market revenue shares and growth opportunities of Ion Sources. Therefore on the basis of key segments such as product type, application, deployment, techniques, key players and key regions, report presents a comprehensive analysis of the market. Furthermore, to study and analyse the global Ion Sources market size on the basis of history data from base year 2019 to 2020-25 covered in this report. By SWOT analysis and development plans report focuses on the Ion Sources players describe market share and market competition landscape.

Global Ion Sources Market Split by Product Type and Applications:

On the basis of Types: Electron Ionization Chemical Ionization Gas Discharge Ion Sources Others

On the basis of Application: Mass Spectrometers Optical Emission Spectrometers Particle Accelerators Ion Implanters

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.innovateinsights.com/report/global-ion-sources-market-status-by-manufacturers-types/98305/#buyinginquiry

Moreover Global Ion Sources Market strategically outlines the key players and comprehensively study their growth strategies. Besides, analysis also forecasts the Compound annual growth rate in terms of revenue at which the Ion Sources is expected to stand and major factors which are driving the markets growth during the forecast period. Report helps the manufacturers to analyse the sales, revenue of the companies in various key regions and key countries, price of platforms and revenues over the forecast period. Reports offers a panorama about the competitive situation among the manufacturers around the globe.

Geographically, the detailed analysis of consumption, revenue, Ion Sources market share and growth rate, historic and forecast (2015-2026) of the following regions are covered-

This research report provides an extensive examination of the global Ion Sources market along with the future projections to estimate the venture feasibility. Additionally, this report includes brief market segmentation study and all the segments. Moreover, the research report is a collection of several factors which are essential for any market movement. Therefore, this Ion Sources report provides the participants with detailed figures at which the Ion Sources market was valued in the historical year and its expected growth in upcoming years. Report presents an overview by researching and examining the market supply. Further by incorporating the feedback of the client report offers the demand and struggle of the market. Moreover report helps customers to understand the structure of Ion Sources market by identifying its various aspects. The study report helps participants to expand their business across the globe by targeting niche markets.

Read the original post:

Global Ion Sources Market 2020 to Witness Huge Growth by 2026 | Top Key Players; Hitachi High-Technologies, Evans Analytical Group, Fibics...

Read the Rest...

COVID-19 Impacts: Scanning Electron Microscope Market Will Accelerate at a CAGR of almost 8% through 2020-2024 | Increasing Focus on Nanotechnology to…

§ August 10th, 2020 § Filed under Nanotech Comments Off on COVID-19 Impacts: Scanning Electron Microscope Market Will Accelerate at a CAGR of almost 8% through 2020-2024 | Increasing Focus on Nanotechnology to…

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the scanning electron microscope market and it is poised to grow by USD 727.60 million during 2020-2024, progressing at a CAGR of almost 8% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact

Frequently Asked Questions-

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Advantest Corp., Carl Zeiss AG, Danaher Corp., DELONG INSTRUMENTS AS, Hitachi High-Technologies Corp., JEOL Ltd., Keysight Technologies Inc., Nikon Corp., TESCAN ORSAY HOLDING AS, and Thermo Fisher Scientific Inc. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Increasing focus on nanotechnology has been instrumental in driving the growth of the market.

Scanning Electron Microscope Market 2020-2024: Segmentation

Scanning Electron Microscope Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40449

Scanning Electron Microscope Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our scanning electron microscope market report covers the following areas:

This study identifies the emergence of containerized data centers as one of the prime reasons driving the scanning electron microscope market growth during the next few years.

Scanning Electron Microscope Market 2020-2024: Vendor Analysis

We provide a detailed analysis of vendors operating in the scanning electron microscope market, including some of the vendors such as Advantest Corp., Carl Zeiss AG, Danaher Corp., DELONG INSTRUMENTS AS, Hitachi High-Technologies Corp., JEOL Ltd., Keysight Technologies Inc., Nikon Corp., TESCAN ORSAY HOLDING AS, and Thermo Fisher Scientific Inc. Backed with competitive intelligence and benchmarking, our research reports on the scanning electron microscope market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Scanning Electron Microscope Market 2020-2024: Key Highlights

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by End-user

Customer Landscape

Geographic Landscape

Drivers, Challenges, and Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Follow this link:

COVID-19 Impacts: Scanning Electron Microscope Market Will Accelerate at a CAGR of almost 8% through 2020-2024 | Increasing Focus on Nanotechnology to...

Read the Rest...

Trending: Non-Glass Capacitive Sensors Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 | Apple, Rubicon Technology,…

§ August 10th, 2020 § Filed under Nanotech Comments Off on Trending: Non-Glass Capacitive Sensors Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 | Apple, Rubicon Technology,…

LOS ANGELES, United States: QY Research has recently published a report, titled Global Non-Glass Capacitive Sensors Market Research Report 2020. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Non-Glass Capacitive Sensors market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Non-Glass Capacitive Sensors market include: Apple, Rubicon Technology, GT Advanced Technologies, Graphenea, Cambrios Technologies, TPK Holdings, Iljin Display, Canatu, Cima NanoTech

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1582711/global-non-glass-capacitive-sensors-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Non-Glass Capacitive Sensors market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Non-Glass Capacitive Sensors Market Segment By Type:

Plastic Polymer Sapphire

Global Non-Glass Capacitive Sensors Market Segment By Application:

Education Manufacturing Retail Others

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Non-Glass Capacitive Sensors market.

Key companies operating in the global Non-Glass Capacitive Sensors market include Apple, Rubicon Technology, GT Advanced Technologies, Graphenea, Cambrios Technologies, TPK Holdings, Iljin Display, Canatu, Cima NanoTech

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1582711/global-non-glass-capacitive-sensors-market

TOC

1 Non-Glass Capacitive Sensors Market Overview 1.1 Product Overview and Scope of Non-Glass Capacitive Sensors 1.2 Non-Glass Capacitive Sensors Segment by Type 1.2.1 Global Non-Glass Capacitive Sensors Production Growth Rate Comparison by Type 2020 VS 2026 1.2.2 Plastic 1.2.3 Polymer 1.2.4 Sapphire 1.3 Non-Glass Capacitive Sensors Segment by Application 1.3.1 Non-Glass Capacitive Sensors Consumption Comparison by Application: 2020 VS 2026 1.3.2 Education 1.3.3 Manufacturing 1.3.4 Retail 1.3.5 Others 1.4 Global Non-Glass Capacitive Sensors Market by Region 1.4.1 Global Non-Glass Capacitive Sensors Market Size Estimates and Forecasts by Region: 2020 VS 2026 1.4.2 North America Estimates and Forecasts (2015-2026) 1.4.3 Europe Estimates and Forecasts (2015-2026) 1.4.4 China Estimates and Forecasts (2015-2026) 1.4.5 Japan Estimates and Forecasts (2015-2026) 1.4.6 South Korea Estimates and Forecasts (2015-2026) 1.5 Global Non-Glass Capacitive Sensors Growth Prospects 1.5.1 Global Non-Glass Capacitive Sensors Revenue Estimates and Forecasts (2015-2026) 1.5.2 Global Non-Glass Capacitive Sensors Production Capacity Estimates and Forecasts (2015-2026) 1.5.3 Global Non-Glass Capacitive Sensors Production Estimates and Forecasts (2015-2026) 1.6 Non-Glass Capacitive Sensors Industry 1.7 Non-Glass Capacitive Sensors Market Trends 2 Market Competition by Manufacturers 2.1 Global Non-Glass Capacitive Sensors Production Capacity Market Share by Manufacturers (2015-2020) 2.2 Global Non-Glass Capacitive Sensors Revenue Share by Manufacturers (2015-2020) 2.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.4 Global Non-Glass Capacitive Sensors Average Price by Manufacturers (2015-2020) 2.5 Manufacturers Non-Glass Capacitive Sensors Production Sites, Area Served, Product Types 2.6 Non-Glass Capacitive Sensors Market Competitive Situation and Trends 2.6.1 Non-Glass Capacitive Sensors Market Concentration Rate 2.6.2 Global Top 3 and Top 5 Players Market Share by Revenue 2.6.3 Mergers & Acquisitions, Expansion 3 Production and Capacity by Region 3.1 Global Production Capacity of Non-Glass Capacitive Sensors Market Share by Regions (2015-2020) 3.2 Global Non-Glass Capacitive Sensors Revenue Market Share by Regions (2015-2020) 3.3 Global Non-Glass Capacitive Sensors Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.4 North America Non-Glass Capacitive Sensors Production 3.4.1 North America Non-Glass Capacitive Sensors Production Growth Rate (2015-2020) 3.4.2 North America Non-Glass Capacitive Sensors Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.5 Europe Non-Glass Capacitive Sensors Production 3.5.1 Europe Non-Glass Capacitive Sensors Production Growth Rate (2015-2020) 3.5.2 Europe Non-Glass Capacitive Sensors Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.6 China Non-Glass Capacitive Sensors Production 3.6.1 China Non-Glass Capacitive Sensors Production Growth Rate (2015-2020) 3.6.2 China Non-Glass Capacitive Sensors Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.7 Japan Non-Glass Capacitive Sensors Production 3.7.1 Japan Non-Glass Capacitive Sensors Production Growth Rate (2015-2020) 3.7.2 Japan Non-Glass Capacitive Sensors Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.8 South Korea Non-Glass Capacitive Sensors Production 3.8.1 South Korea Non-Glass Capacitive Sensors Production Growth Rate (2015-2020) 3.8.2 South Korea Non-Glass Capacitive Sensors Production Capacity, Revenue, Price and Gross Margin (2015-2020) 4 Global Non-Glass Capacitive Sensors Consumption by Regions 4.1 Global Non-Glass Capacitive Sensors Consumption by Regions 4.1.1 Global Non-Glass Capacitive Sensors Consumption by Region 4.1.2 Global Non-Glass Capacitive Sensors Consumption Market Share by Region 4.2 North America 4.2.1 North America Non-Glass Capacitive Sensors Consumption by Countries 4.2.2 U.S. 4.2.3 Canada 4.3 Europe 4.3.1 Europe Non-Glass Capacitive Sensors Consumption by Countries 4.3.2 Germany 4.3.3 France 4.3.4 U.K. 4.3.5 Italy 4.3.6 Russia 4.4 Asia Pacific 4.4.1 Asia Pacific Non-Glass Capacitive Sensors Consumption by Region 4.4.2 China 4.4.3 Japan 4.4.4 South Korea 4.4.5 Taiwan 4.4.6 Southeast Asia 4.4.7 India 4.4.8 Australia 4.5 Latin America 4.5.1 Latin America Non-Glass Capacitive Sensors Consumption by Countries 4.5.2 Mexico 4.5.3 Brazil 5 Non-Glass Capacitive Sensors Production, Revenue, Price Trend by Type 5.1 Global Non-Glass Capacitive Sensors Production Market Share by Type (2015-2020) 5.2 Global Non-Glass Capacitive Sensors Revenue Market Share by Type (2015-2020) 5.3 Global Non-Glass Capacitive Sensors Price by Type (2015-2020) 5.4 Global Non-Glass Capacitive Sensors Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 6 Global Non-Glass Capacitive Sensors Market Analysis by Application 6.1 Global Non-Glass Capacitive Sensors Consumption Market Share by Application (2015-2020) 6.2 Global Non-Glass Capacitive Sensors Consumption Growth Rate by Application (2015-2020) 7 Company Profiles and Key Figures in Non-Glass Capacitive Sensors Business 7.1 Apple 7.1.1 Apple Non-Glass Capacitive Sensors Production Sites and Area Served 7.1.2 Apple Non-Glass Capacitive Sensors Product Introduction, Application and Specification 7.1.3 Apple Non-Glass Capacitive Sensors Production Capacity, Revenue, Price and Gross Margin (2015-2020) 7.1.4 Apple Main Business and Markets Served 7.2 Rubicon Technology 7.2.1 Rubicon Technology Non-Glass Capacitive Sensors Production Sites and Area Served 7.2.2 Rubicon Technology Non-Glass Capacitive Sensors Product Introduction, Application and Specification 7.2.3 Rubicon Technology Non-Glass Capacitive Sensors Production Capacity, Revenue, Price and Gross Margin (2015-2020) 7.2.4 Rubicon Technology Main Business and Markets Served 7.3 GT Advanced Technologies 7.3.1 GT Advanced Technologies Non-Glass Capacitive Sensors Production Sites and Area Served 7.3.2 GT Advanced Technologies Non-Glass Capacitive Sensors Product Introduction, Application and Specification 7.3.3 GT Advanced Technologies Non-Glass Capacitive Sensors Production Capacity, Revenue, Price and Gross Margin (2015-2020) 7.3.4 GT Advanced Technologies Main Business and Markets Served 7.4 Graphenea 7.4.1 Graphenea Non-Glass Capacitive Sensors Production Sites and Area Served 7.4.2 Graphenea Non-Glass Capacitive Sensors Product Introduction, Application and Specification 7.4.3 Graphenea Non-Glass Capacitive Sensors Production Capacity, Revenue, Price and Gross Margin (2015-2020) 7.4.4 Graphenea Main Business and Markets Served 7.5 Cambrios Technologies 7.5.1 Cambrios Technologies Non-Glass Capacitive Sensors Production Sites and Area Served 7.5.2 Cambrios Technologies Non-Glass Capacitive Sensors Product Introduction, Application and Specification 7.5.3 Cambrios Technologies Non-Glass Capacitive Sensors Production Capacity, Revenue, Price and Gross Margin (2015-2020) 7.5.4 Cambrios Technologies Main Business and Markets Served 7.6 TPK Holdings 7.6.1 TPK Holdings Non-Glass Capacitive Sensors Production Sites and Area Served 7.6.2 TPK Holdings Non-Glass Capacitive Sensors Product Introduction, Application and Specification 7.6.3 TPK Holdings Non-Glass Capacitive Sensors Production Capacity, Revenue, Price and Gross Margin (2015-2020) 7.6.4 TPK Holdings Main Business and Markets Served 7.7 Iljin Display 7.7.1 Iljin Display Non-Glass Capacitive Sensors Production Sites and Area Served 7.7.2 Iljin Display Non-Glass Capacitive Sensors Product Introduction, Application and Specification 7.7.3 Iljin Display Non-Glass Capacitive Sensors Production Capacity, Revenue, Price and Gross Margin (2015-2020) 7.7.4 Iljin Display Main Business and Markets Served 7.8 Canatu 7.8.1 Canatu Non-Glass Capacitive Sensors Production Sites and Area Served 7.8.2 Canatu Non-Glass Capacitive Sensors Product Introduction, Application and Specification 7.8.3 Canatu Non-Glass Capacitive Sensors Production Capacity, Revenue, Price and Gross Margin (2015-2020) 7.8.4 Canatu Main Business and Markets Served 7.9 Cima NanoTech 7.9.1 Cima NanoTech Non-Glass Capacitive Sensors Production Sites and Area Served 7.9.2 Cima NanoTech Non-Glass Capacitive Sensors Product Introduction, Application and Specification 7.9.3 Cima NanoTech Non-Glass Capacitive Sensors Production Capacity, Revenue, Price and Gross Margin (2015-2020) 7.9.4 Cima NanoTech Main Business and Markets Served 8 Non-Glass Capacitive Sensors Manufacturing Cost Analysis 8.1 Non-Glass Capacitive Sensors Key Raw Materials Analysis 8.1.1 Key Raw Materials 8.1.2 Key Raw Materials Price Trend 8.1.3 Key Suppliers of Raw Materials 8.2 Proportion of Manufacturing Cost Structure 8.3 Manufacturing Process Analysis of Non-Glass Capacitive Sensors 8.4 Non-Glass Capacitive Sensors Industrial Chain Analysis 9 Marketing Channel, Distributors and Customers 9.1 Marketing Channel 9.2 Non-Glass Capacitive Sensors Distributors List 9.3 Non-Glass Capacitive Sensors Customers 10 Market Dynamics 10.1 Market Trends 10.2 Opportunities and Drivers 10.3 Challenges 10.4 Porters Five Forces Analysis 11 Production and Supply Forecast 11.1 Global Forecasted Production of Non-Glass Capacitive Sensors (2021-2026) 11.2 Global Forecasted Revenue of Non-Glass Capacitive Sensors (2021-2026) 11.3 Global Forecasted Price of Non-Glass Capacitive Sensors (2021-2026) 11.4 Global Non-Glass Capacitive Sensors Production Forecast by Regions (2021-2026) 11.4.1 North America Non-Glass Capacitive Sensors Production, Revenue Forecast (2021-2026) 11.4.2 Europe Non-Glass Capacitive Sensors Production, Revenue Forecast (2021-2026) 11.4.3 China Non-Glass Capacitive Sensors Production, Revenue Forecast (2021-2026) 11.4.4 Japan Non-Glass Capacitive Sensors Production, Revenue Forecast (2021-2026) 11.4.5 South Korea Non-Glass Capacitive Sensors Production, Revenue Forecast (2021-2026) 12 Consumption and Demand Forecast 12.1 Global Forecasted and Consumption Demand Analysis of Non-Glass Capacitive Sensors 12.2 North America Forecasted Consumption of Non-Glass Capacitive Sensors by Country 12.3 Europe Market Forecasted Consumption of Non-Glass Capacitive Sensors by Country 12.4 Asia Pacific Market Forecasted Consumption of Non-Glass Capacitive Sensors by Regions 12.5 Latin America Forecasted Consumption of Non-Glass Capacitive Sensors 13 Forecast by Type and by Application (2021-2026) 13.1 Global Production, Revenue and Price Forecast by Type (2021-2026) 13.1.1 Global Forecasted Production of Non-Glass Capacitive Sensors by Type (2021-2026) 13.1.2 Global Forecasted Revenue of Non-Glass Capacitive Sensors by Type (2021-2026) 13.1.2 Global Forecasted Price of Non-Glass Capacitive Sensors by Type (2021-2026) 13.2 Global Forecasted Consumption of Non-Glass Capacitive Sensors by Application (2021-2026) 14 Research Finding and Conclusion 15 Methodology and Data Source 15.1 Methodology/Research Approach 15.1.1 Research Programs/Design 15.1.2 Market Size Estimation 15.1.3 Market Breakdown and Data Triangulation 15.2 Data Source 15.2.1 Secondary Sources 15.2.2 Primary Sources 15.3 Author List 15.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See original here:

Trending: Non-Glass Capacitive Sensors Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 | Apple, Rubicon Technology,...

Read the Rest...

Plus Therapeutics Reports Second Quarter 2020 Financial and Business Results – BioSpace

§ August 10th, 2020 § Filed under Nanotech Comments Off on Plus Therapeutics Reports Second Quarter 2020 Financial and Business Results – BioSpace

AUSTIN, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), today announced financial and business results for its Second Quarter Fiscal Year 2020 ended June 30, 2020.

Q2 2020 net loss was $1.8 million, or $0.45 per share, including payments to NanoTx LLC of $0.78 million. Net cash used in operating activities for the six months ended June 30, 2020 was approximately $2.9 million. Plus Therapeutics ended Q2 2020 with approximately $9.3 million of cash and cash equivalents.

The Plus Therapeutics portfolio has three clinical-stage injectable drugs being developed on a unique nanotechnology platform designed to provide patient benefits through improved formulation and delivery innovation. The Company believes the platform can enable significant potential enhancements of safety, efficacy and convenience for oncology patients and their health providers compared to current standards of care.

The lead investigational drug in the Companys licensed radiotherapeutic portfolio is Rhenium NanoLiposomes (RNL), a nanoliposome-encapsulated radionuclide for several cancer targets. Initially being developed for the treatment of recurrent glioblastoma, RNL is being evaluated in the U.S. NIH/NCI-supported, multi-center ReSPECT Phase 1 dose-finding clinical trial (NCT01906385). RNL is designed to safely, effectively, and conveniently deliver a very high dose of radiation directly into the brain tumor that is up to 25 times greater than that currently being given to recurrent glioblastoma patients using external beam radiation therapy.

H2 2020 Business Expansion Outlook

The first half of Fiscal Year 2020 marked the successful implementation of the Companys refined development focus, initial pipeline expansion and optimized cost structure. In the second half of Fiscal Year 2020, the Company intends to focus on a number of additional business objectives and potential milestones:

Following the close of our most recent in-licensing transaction, we have made steady progress in expediting the ReSPECT trial, said Dr. Marc Hedrick, President and Chief Executive Officer of Plus Therapeutics. The second half of 2020 includes the prospect of further significant advancement for our RNL program-- and for the Company. We believe RNL has the potential of improving brain tumor therapy and that of other difficult to treat radiosensitive tumors.

Q2 2020 Financial Highlights

Investor Call Today at 5 p.m. EDT

The Company plans to hold a conference call and live audio webcast today at 5:00 PM Eastern Time to discuss its financial results and provide a general business update.

About Plus Therapeutics, Inc.

Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Companys drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found atwww.plustherapeutics.com and http://www.respect-trials.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains statements that may be deemed forward-looking statements within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as will, believe, plan, can, enable, design, intend, potential, expect, estimate, project, prospect, target, focus, anticipate, could, should, and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the design and potential of the Plus Therapeutics portfolio to reformulate, deliver and commercialize multiple novel, proprietary drugs targeting rare cancers and other diseases and to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs; the Companys belief as to the platforms capacity to leverage new delivery approaches and/or formulations to enable significant potential enhancements of safety, efficacy and convenience for patients and healthcare providers; the potential of the Companys portfolio generally, and the potential of RNL to safely and effectively deliver a dose of radiation directly to the tumor up to 25 times greater than that currently being given to patients using external beam radiation therapy; the Companys belief as to the potential of RNL to improve brain tumor therapy and that of other difficult to treat radiosensitive tumors; the timing, status, outcome, and anticipated expansion of clinical trials for RNL, including the planned initiation of an additional Phase 1 study and enrollment at additional sites, and the anticipated timing thereof; the Companys business expansion outlook for the second half of 2020, including its intended focus on certain additional business expansion milestones; the Companys expectations regarding the progress and prospect of advancement for the Company, RNL, and the Companys portfolio during the second half of 2020; and the potential impact of the COVID-19 pandemic on the Company and its clinical programs, operating results, and financial condition. The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDAs accelerated regulatory pathways; the early stage of the Companys product candidates and therapies, the results of its research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Companys history of losses; the Companys need for, and ability to raise, additional cash or obtain other sources of funding; the Companys ability to: (a) obtain and maintain regulatory approvals, (b) continue as a going concern, (c) remain listed on the Nasdaq Capital Market, (d) to obtain or maintain sufficient levels of reimbursement for its tests, and (d) to repay or refinance some or all of its outstanding indebtedness; the outcome of the Companys partnering/licensing efforts; market and economic conditions; the impact of the COVID-19 pandemic on the Company and the effectiveness of the efforts it has taken or may take in the future in response thereto; and additional risks described under the heading Risk Factors in the Companys Securities and Exchange Commission filings, including in the Companys annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Contact: Plus Therapeutics, Inc. Andrew Sims VP Chief Financial Officer, Investor Relations Phone: +1.619.333.4150 Email:ir@plustherapeutics.com Corporate Website:plustherapeutics.com Clinical Website: respect-trials.com

Link:

Plus Therapeutics Reports Second Quarter 2020 Financial and Business Results - BioSpace

Read the Rest...

IIT Guwahati becomes the first institute to produce Covid-19 diagnostic kits – Deccan Herald

§ August 10th, 2020 § Filed under Nanotech Comments Off on IIT Guwahati becomes the first institute to produce Covid-19 diagnostic kits – Deccan Herald

The Indian Institute of Technology Guwahati (IITG) along with RR Animal Healthcare Ltd. has jointly developed affordable Covid-19 related diagnostic kits and already supplied to Assam health department.

A statement issued by IITG said it became the first institute in the country to demonstrate an efficient model to develop import-substitute Covid-19 kits from lab-scale to prototype level, field/hospital testing and commercialising thereby saving valuable foreign exchange for the country, timely delivery and customising as per the needs of the user.

"These kits, being developed presently at the Center of Nanotechnology, IIT Guwahati, are now supplied regularly in large quantities to the National Health Mission, Assam and several hospitals across the country," it said.

For latest updates on coronavirus outbreak, click here

Initially, these included the ICMR approved SPILD Viral Transport Media (VTM) Kits. Over the past several months, with the lockdown being implemented across the country and with very less air connectivity, acquiring large quantities of Covid-19 kits became very difficult.

To overcome this crisis, the National Health Mission, Assam had approached Prof. T. G. Sitharam, director, IIT Guwahati, with a request to develop VVTM kits, RNA extraction kits and RT-PCR kits and help the state government in their efforts to overcome this shortage.

IIT Guwahati immediately took up this challenge and strategised to develop these kits in-house to meet the growing requirement of these kits during this time of Covid-19 pandemic, said the statement.

The IITG said more than 2.5 Lakhs VTM kits have already been supplied to NHM, Assam. Several testing laboratories across the country have also started procuring these import substitute kits due to their high quality, affordable price and timely delivery schedules.

"The performance of the indigenously developed RNA extraction kits have also been highly satisfactory as per the Guwahati Medical College and Hospital and the institute has started supplying these RNA extraction kits in large quantities to the state government. Similarly, the indigenously developed RT-PCR kits are being validated presently and the production, as well as supply of these kits is likely to commence soon," it said.

These affordable and sterile SPILD Viral VTM kits, RT-PCR kits and RNA isolation kits have been developed at the Center for Nanotechnology, IIT Guwahati, jointly with RR Animal Healthcare Ltd. with inputs from GMCH by the research teams led by Prof. Parameswar Krishnan Iyer, Prof. Siddhartha Sankar Ghosh from IIT Guwahati and Dr Labanyamoy Kole and Dr Debashish Dutta of RR Animal Healthcare.

Read this article:

IIT Guwahati becomes the first institute to produce Covid-19 diagnostic kits - Deccan Herald

Read the Rest...

Global Nanotechnology in Medical Devices Market Is Set for a Rapid Growth and is Expected to Reach USD Billion by 2027: Stryker Corporation , 3M…

§ August 10th, 2020 § Filed under Nanotech Comments Off on Global Nanotechnology in Medical Devices Market Is Set for a Rapid Growth and is Expected to Reach USD Billion by 2027: Stryker Corporation , 3M…

Global "Nanotechnology in Medical Devices Market" research report has all the necessary vital details asked by the clients or any audiences in terms of market advantages or disadvantages and future market scope all mentioned in a very crystal clear manner. The report eloquently mentioned all the information regarding market competitors, growth rate, revenue ups and downs, regional players, industrial players, and applications. Even the most measly information depicting market figures are comprehensively analyzed and before being presented to the clients. The industrial players Stryker Corporation (U.S.), 3M Company (U.S.), St. Jude Medical, Inc. (U.S.), Affymetrix, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Starkey Hearing Technologies (U.S.), Smith & Nephew plc (U.K.)., Dentsply International, Mitsui Chemicals, Inc., AAP Implantate AG are all provided so as to make it easier for the audiences to understand the market growth rate. The current Nanotechnology in Medical Devices market research report has demonstrated all the vital market growth factors and economic fluctuations mentioned owing to the immense attention gained in recent years.

Click HereTo Access The Sample Report::

Global Market portal aims to provide reports like these in order to draw the attention of many of the clients wanting to extrapolate some of the vital details of the Nanotechnology in Medical Devices market on a global scale. The Nanotechnology in Medical Devices market dossier talks about the market segmentation created on the basis of consensus made, product type, government norms, key industrial players, competitive landscapes, applications, end-user, topological players, and more. The report presents a demand for individual segment in each region. It demonstrates various segments Active Implantable Medical Devices, Biochip, Portable Material and sub-segments Treatment Using, Diagnostic Using, Research Using of the global Nanotechnology in Medical Devices market. The current report data simulates the market status and investment gains or losses in a very illustrative manner so as to provide the analyzed data in a very refreshed format.

Read Detailed Index Of Full Research Study @:: http://www.reportsbuzz.com/53388/global-nanotechnology-in-medical-devices-market-outlook-2018/

Though the paper may have certain limitations in terms of providing the information, the record has purported all the deep-seated intricate information. The clients and other readers can have all the global Nanotechnology in Medical Devices market highlights provided in this very report. The geographical regions also play an important role in enhancing the growth and development of the global Nanotechnology in Medical Devices market. The report has all the vital information regarding supply and demand, market development enhancers, market share, sales distributors, and more advocated in a very formal pattern.

There are 15 Chapters to display the Global Nanotechnology in Medical Devices market

Chapter 1, Definition, Specifications and Classification of Nanotechnology in Medical Devices , Applications of Nanotechnology in Medical Devices , Market Segment by Regions; Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure; Chapter 3, Technical Data and Manufacturing Plants Analysis of Nanotechnology in Medical Devices , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis; Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment); Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Nanotechnology in Medical Devices Segment Market Analysis (by Type); Chapter 7 and 8, The Nanotechnology in Medical Devices Segment Market Analysis (by Application) Major Manufacturers Analysis of Nanotechnology in Medical Devices ; Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Active Implantable Medical Devices, Biochip, Portable Material, Market Trend by Application Treatment Using, Diagnostic Using, Research Using; Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis; Chapter 11, The Consumers Analysis of Global Nanotechnology in Medical Devices ; Chapter 12, Nanotechnology in Medical Devices Research Findings and Conclusion, Appendix, methodology and data source; Chapter 13, 14 and 15, Nanotechnology in Medical Devices sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquire Here Get customization & check discount for report @: http://www.reportsbuzz.com/inquiry-for-buying.html?repid=53388

See the rest here:

Global Nanotechnology in Medical Devices Market Is Set for a Rapid Growth and is Expected to Reach USD Billion by 2027: Stryker Corporation , 3M...

Read the Rest...

Global Tactical and Outdoor Clothing Market 2020-2024: Smart Technologies and Flame-Resistant Tactical Clothing Key Growth Factors – PRNewswire

§ August 10th, 2020 § Filed under Nanotech Comments Off on Global Tactical and Outdoor Clothing Market 2020-2024: Smart Technologies and Flame-Resistant Tactical Clothing Key Growth Factors – PRNewswire

DUBLIN, Aug. 10, 2020 /PRNewswire/ -- The "Global Tactical and Outdoor Clothing Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

The tactical and outdoor clothing market is forecast to show significant growth during the period 2020-2024. This research analyzes the current global market scenario, latest drivers and restraints to provide current market analysis as well as expected market situation in future.

The geographic regions covered in the global tactical and outdoor clothing market includes: North America, South America, Europe, Asia Pacific (APAC), and Middle East and Africa (MEA)

Evolution of protective and nanotechnology clothing is recognized as one of the key driving factor for tactical and outdoor clothing market growth over the forecast period.

Smart technologies in tactical and outdoor clothing, and emergence of flame-resistant tactical clothing, will be some of the other factors impacting the market growth.

To strengthen their market position, many vendors are increasing investment. The investments are targeted to increase capacity or improve distribution network and logistics & warehousing. Based on detailed study of the market, vendors product offering and their geographical presence. Decathlon, Luxottica Group (Oakley), Propper, and Under Armour were identified as some of the prominent players in this market.

The 2020-2024 report on global tactical and outdoor clothing market provides:

Key Topics Covered:

1 Executive Summary

2 Market Landscape 2.1 Market Ecosystem 2.2 Market Characteristics 2.3 Value Chain Analysis

3 Market Sizing 3.1 Market Definition 3.2 Market Segmentation Analysis 3.3 Market Size 2019 3.4 Market Outlook: Forecast 2019-2024

4 Five Forces Analysis 4.1 Bargaining Power of Buyers 4.2 Bargaining Power of Suppliers 4.3 Threat of New Entrants 4.4 Threat of Substitutes 4.5 Threat of Rivalry 4.6 Market Condition

5 Market Segmentation

6 Customer Landscape

7 Geographic Landscape 7.1 Geographic Segmentation 7.2 Geographic Comparison 7.3 Europe - Market Size and Forecast 2019-2024 7.4 North America - Market Size and Forecast 2019-2024 7.5 APAC - Market Size and Forecast 2019-2024 7.6 South America - Market Size and Forecast 2019-2024 7.7 MEA - Market Size and Forecast 2019-2024 7.8 Key Leading Countries 7.9 Market Opportunity

8 Drivers, Challenges and Trends 8.1 Market Drivers 8.2 Market Challenges 8.3 Market Trends

9 Vendor landscape 9.1 Overview 9.2 Landscape Disruption

10 Vendor Analysis 10.1 Vendors Covered 10.2 Market Positioning of Vendors

11 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/6ie97w

About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

View original post here:

Global Tactical and Outdoor Clothing Market 2020-2024: Smart Technologies and Flame-Resistant Tactical Clothing Key Growth Factors - PRNewswire

Read the Rest...

Global Impact of Covid-19 on Airgel Insulation Material Market to Record Significant Revenue Growth During the Forecast Period 20202025 |…

§ August 10th, 2020 § Filed under Nanotech Comments Off on Global Impact of Covid-19 on Airgel Insulation Material Market to Record Significant Revenue Growth During the Forecast Period 20202025 |…

Latest Research Report: Airgel Insulation Material industry

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

Global Airgel Insulation Material Market documents a detailed study of different aspects of the Global Market. It shows the steady growth in market in spite of the fluctuations and changing market trends. The report is based on certain important parameters.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/110421

Airgel Insulation Material Market competition by top manufacturers as follow: , AspenAerogel, BASF, NANO TECH, BCEGC, Surnano, NICHIAS

The risingtechnology in Airgel Insulation Materialmarketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail. It includes a meticulous analysis of market trends, market shares and revenue growth patterns and the volume and value of the market. It is also based on a meticulously structured methodology. These methods help to analyze markets on the basis of thorough research and analysis.

The Type Coverage in the Market are: Soundproof Type Waterproof Type

Market Segment by Applications, covers: Construction Automotive Fire Facilities Home Appliances Electronic Machinery Manufacturing

The research report summarizes companies from different industries. This Airgel Insulation Material Market report has been combined with a variety of market segments such as applications, end users and sales. Focus on existing market analysis and future innovation to provide better insight into your business. This study includes sophisticated technology for the market and diverse perspectives of various industry professionals.

Airgel Insulation Material is the arena of accounting worried with the summary, analysis and reporting of financial dealings pertaining to a business. This includes the training of financial statements available for public ingesting. The service involves brief, studying, checking and reporting of the financial contacts to tax collection activities and objects. It also involves checking and making financial declarations, scheming accounting systems, emerging finances and accounting advisory.

To get this report at a profitable rate.: https://reportsinsights.com/discount/110421

Market segment by Regions/Countries, this report covers North America Europe China Rest of Asia Pacific Central & South America Middle East & Africa

Report Highlights: Detailed overview of parent market Changing market dynamics in the industry In-depth market segmentation Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape Strategies of key players and products offered Potential and niche segments, geographical regions exhibiting promising growth A neutral perspective on market performance Must-have information for market players to sustain and enhance their market footprint

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Airgel-Insulation-Material-Market-110421

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

See the original post here:

Global Impact of Covid-19 on Airgel Insulation Material Market to Record Significant Revenue Growth During the Forecast Period 20202025 |...

Read the Rest...

IIT Delhi, OUAT Bhubaneswar Sign MoU for Strengthening Research & Education in Cutting Edge Areas of Agriculture and Allied Subjects – India…

§ August 10th, 2020 § Filed under Nanotech Comments Off on IIT Delhi, OUAT Bhubaneswar Sign MoU for Strengthening Research & Education in Cutting Edge Areas of Agriculture and Allied Subjects – India…

New Delhi: Indian Institute of Technology (IIT) Delhi and Odisha University of Agriculture and Technology (OUAT), Bhubaneswar have signed a Memorandum of Understanding (MoU) to generate frontier technologies and produce quality human resources in the field of agricultural research and education for addressing the challenges faced by the rural communities and improving their quality of life.

OUAT, Bhubaneswar and IIT Delhi would work jointly in the field of Sensor Application in Agriculture, Precision Farming, Geospatial Technology, Nanotechnology, Biotechnology, and related aspects of agriculture, leading to the creation of rural livelihood opportunities. There will be a strengthening of faculty/ scientists through exchange programmes and the use of laboratories of both the organisations.

The MoU was signed by Prof. V. Ramgopal Rao, Director, IIT Delhi and Dr. Pawan Kumar Agrawal, Vice-Chancellor, OUAT Bhubaneswar.

After signing the MoU, Dr. P.K. Agrawal, Vice-Chancellor, OUAT expressed that this collaboration will create new avenues for interdisciplinary research with the involvement of scientists from OUAT and IIT Delhi.

Speaking of the MoU, Prof. Rao, Director, IIT Delhi said, As part of IIT Delhis resolve to strengthen the rural economy through technology interventions, the institute is closely working with multiple ICAR laboratories on a variety of agricultural problems. Through this collaborative agreement with OUAT, we hope to also initiate multiple funded projects between IIT Delhi and OUAT faculty under IIT Delhis Faculty Interdisciplinary Research Programme (FIRP).

The academic and research collaborations between OUAT and IIT Delhi especially in the areas of sensor based agricultural technologies, nanotechnology and biotechnology applications will develop strategies and modern techniques for meeting current challenges faced by agricultural sectors, said Prof. Sunil Kr. Khare, Dean, R&D, IIT Delhi.

There will also be a joint venture to operate research projects having a common interest in both the institutions.

See original here:

IIT Delhi, OUAT Bhubaneswar Sign MoU for Strengthening Research & Education in Cutting Edge Areas of Agriculture and Allied Subjects - India...

Read the Rest...

Hoth Therapeutics Licenses Intellectual Property to Develop Real-time, Breath-Based COVID-19 Mobile Testing Device – PRNewswire

§ August 10th, 2020 § Filed under Nanotech Comments Off on Hoth Therapeutics Licenses Intellectual Property to Develop Real-time, Breath-Based COVID-19 Mobile Testing Device – PRNewswire

NEW YORK, Aug. 10, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company,today announced licensing the intellectual property rights relating to the development of a medical device that has the potential to allow public health professionals to immediately diagnose COVID-19 infection via breath sample and track through a mobile device from the George Washington University ('GW').

Dr. Mona E. Zaghloul, a professor of Electrical and Computer Engineering at GW School of Engineering and Applied Science, and her former doctoral student Yangyang Zhao,developed the design of the device, based on prior work of other former students, in collaboration with the National Institute of Standards and Technologyto detect and distinguish different species of gas. The device is based on nanotechnology Nanoholes using Plasmonics principles. The surface of the device is covered in a thin sheet of gold that can bind with other molecules, like those of a gas. Once the binding occurs, the wavelength of light bouncing off the surface changes, creating a different color of light. Different gases would cause different shifts in light. The results can be available quickly, and artificial intelligence programs can then classify the molecules that are bound to the surface of the device. The results, including the different classes of the molecules, can then be sent to the cloud by a mobile device, allowing the ability to track the data.

Dr. Jeanne A. Jordan, PhD, a professor in Epidemiology at the GW Milken Institute School of Public Health, was instrumental in recognizing the potential diagnostic capabilities of the technology. As the COVID-19 pandemic spread, she suggested alterations to the device. The researchers believe that the modified apparatus, which is as small as a strand of hair, can be coated with a solution designed to bind specifically to the SARS-CoV-2 virus that causes COVID-19. This design would allow the virus to bind to the surface, thereby allowing for the detection of an optical change that could immediately be sensed by phone cameras when an infected person's specimen is applied.

The research by Dr. Zaghloul and Dr. Jordan was funded by a COVID-19 Technology Maturation Grant from GW's Technology Commercialization Office to accelerate the development of this medical device. The device would allow communities to build trackable real-time databases of infection. People can upload information directly to the cloud.

"These are devices that a public health professional could go out with into the field to administer point-of-care testing, either at a walk-up center or directly in the community," Dr. Jordan said. "They're extremely rapidthe turnaround time to having test results is within minutes, and you do the testing right there instead of having to send your sample to a large commercial laboratory with a massive backlog. That would allow these professionals to say immediately if someone needs to be quarantined, and to get the names of their contacts so they can start contact tracing."

Mr.Robb Knie, Chief Executive Officer of Hoth, stated,"The immediate diagnosis and ongoing tracking of COVID-19 is a critical initiative towards mitigating the ongoing spread of COVID-19. This device which is under development would allow users to conduct widespread testing and provide instantaneous results through the administration of a breath sample and tracking through a mobile device. Securing the rights to this paradigm shifting technology in the fight against the global COVID-19 pandemic is a significant opportunity for Hoth and its shareholders. We look forward to working with the team at GW to accelerate the development of this breakthrough technology."

About Hoth Therapeutics, Inc.Hoth Therapeutics, Inc. isa clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development oftwo different vaccine prospects to prevent or treat COVID-19. To learn more, please visitwww.hoththerapeutics.com.

Forward-Looking StatementCertain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this press release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the Securities and Exchange Commission. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:Email:[emailprotected] http://www.hoththerapeutics.com Phone: (678) 570-6791 LR Advisors LLC

SOURCE Hoth Therapeutics, Inc.

Homepage

View original post here:

Hoth Therapeutics Licenses Intellectual Property to Develop Real-time, Breath-Based COVID-19 Mobile Testing Device - PRNewswire

Read the Rest...

« Older Entries Newer Entries »



Page 21«..10..20212223..3040..»